Telix Pharmaceuticals (ASX:TLX) does not expect any material impact on its business or supply chain from the international trade tariffs announced by the US government on April 2, according to a Monday Australian bourse filing.
It noted that it had an extensive US-based manufacturing and distribution infrastructure with third-party manufacturing sites and radiopharmacy partner networks. Pharmaceutical products are currently exempt from the tariffs.
The firm also said that the Food and Drug Administration continues to process applications and information requests, despite reports of changes at the agency, and that the firm has not been notified of any changes to the timelines for its new drug application for Pixclara or biologics license application for Zircaix.
Its shares fell 4% in recent trading on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.